Pfizer and Strata Oncology have expanded their partnership for a clinical trial assessing various cancer therapies in new, biomarker-guided patient groups.
Named Strata Precision Indications for Approved THerapies (Strata PATH), the prospective, pan-tumour therapeutic trial is designed to assess the safety and efficacy of various cancer therapies in these subjects.
It will enrol 700 patients with advanced cancer, as well as early-stage cancer patients with established micrometastatic disease following preliminary treatment.
Various therapeutic classes including targeted antibody-drug conjugates, treatments, angiogenesis inhibitors, and immunotherapies will be assessed in the trial.
All the therapies that are assessed in this trial are approved by the US Food and Drug Administration (FDA) in oncology and have shown safety profiles in the advanced setting.
Subject enrolment into various trial arms is based on new quantitative RNA and multivariate algorithms, developed by Strata.
As part of the expanded collaboration, Pfizer will provide Mektovi (binimetinib), Lorbrena (lorlatinib), and Braftovi (encorafenib) for up to six new cohorts of subjects with early-stage melanoma, lung, colorectal, and other cancers, with micrometastatic disease.
The company has been providing Mektovi (binimetinib), Lorbrena (lorlatinib), Braftovi (encorafenib), Talzenna (talazoparib), and Inlyta (axitinib) to Strata for assessment in four late-stage trial cohorts.
Strata Oncology co-founder and CEO Dan Rhodes said: “The new cohorts of Strata PATH, supported by Pfizer, afford us a very exciting opportunity to move the advances we’ve seen in late-stage cancer into earlier stages of the disease.
“Our goal is to deliver smarter and earlier treatment to every patient and having the support of Pfizer is a testament to the potential of the clinical trials that we are using to accelerate the impact of precision oncology.”
In May this year, the company enrolled the first patient in a prospective, pan-tumour therapeutic trial of various cancer therapies in new, biomarker-guided patient groups.